|
B cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities) |
|
Enduring |
|
$25.00 |
|
Innate immune cell therapies (e.g. activation, inhibition pathways, therapies, toxicities) |
|
Enduring |
|
$25.00 |
|
Innate immune cell therapies (e.g. activation, inhibition pathways, therapies, toxicities) |
|
Enduring |
|
$25.00 |
|
Immunopathology: evaluation, assessment, and considerations |
|
Enduring |
|
$25.00 |
|
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
|
Animal models and species differences (immune system) |
|
Enduring |
|
$25.00 |
|
Definition, history and application of immunosafety in drug development |
|
Enduring |
|
$25.00 |
|
Natural Killer Cells and their use for Cancer Immunotherapy |
|
Enduring |
|
$25.00 |
|
Immune-related adverse events (clinical) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
|
Regulatory guidance: Introduction |
|
Enduring |
|
$25.00 |
|
Regulatory guidance: Introduction |
|
Enduring |
|
$25.00 |
|
A Closer Look at the New ICH E14/S7B Q&As and Training Materials, hosted by HESI and SPS |
|
Enduring |
|
$49.00 |
|
Nonclinical Safety assessment of therapies targeting neoantigens |
|
Enduring |
|
$25.00 |
Facebook
Twitter
LinkedIn
Forward